Chronic Myelogenous Leukemia Treatment

Global Market Trajectory & Analytics

MCP16268

EXECUTIVE ENGAGEMENTS

OUTREACH

2794
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

503
Interactions with Platform & by Email

PARTICIPANTS

84
Unique # Participated

VALIDATIONS

38
Responses Validated*

COMPETITORS

42
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

99

PAGES

171

EDITION

9

PRICE

USD $4950


  

HIGHLIGHTS

Amid the COVID-19 crisis, the global market for Chronic Myelogenous Leukemia Treatment estimated at US$5.3 Billion in the year 2020, is projected to reach a revised size of US$7.6 Billion by 2027, growing at aCAGR of 5.3% over the period 2020-2027. Disease Specific Treatment, one of the segments analyzed in the report, is projected to record 5.9% CAGR and reach US$2.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Symptomatic Treatment segment is readjusted to a revised 5% CAGR for the next 7-year period.
The Chronic Myelogenous Leukemia Treatment market in the U.S. is estimated at US$1.6 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.1% and 4.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

SELECT PLAYERS

Bio-Path Holdings, Inc.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche AG; Incyte Corporation; Novartis AG; Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.

SEGMENTS

» Drug Type (Branded, Generic) » Treatment Type (Disease Specific Treatment, Symptomatic Treatment)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Chronic Myelogenous Leukemia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Disease Specific Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Disease Specific Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Disease Specific Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Symptomatic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Symptomatic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Symptomatic Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Branded by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Branded by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Branded by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Generic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
China Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
France Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Chronic Myelogenous Leukemia Treatment by Treatment Type - Disease Specific Treatment and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Disease Specific Treatment and Symptomatic Treatment for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Chronic Myelogenous Leukemia Treatment by Drug Type - Branded and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Chronic Myelogenous Leukemia Treatment by Drug Type - Percentage Breakdown of Value Sales for Branded and Generic for the Years 2012, 2020 & 2027
Total Companies Profiled: 42

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com